Novo Nordisk has doubled its insulin stockpile in the UK, amid patients' fears that a no-deal Brexit could disrupt supplies of the life-saving medicine, its CEO has said.
Overview
Now more than ever before, biotech is the engine for innovation in medicine, finding, creating and delivering ground-breaking treatments to patients.
The UK government has issued several documents to help businesses in planning for the eventuality of a no-deal Brexit, but the UK’s Brexit Health Alliance says “the guidance is a first step
